South Korea's pharmaceutical and biotechnology industries are researching the potential of obesity drug candidates to treat a range of chronic diseases. They are evaluating treatment effects in clinical trials for liver disease, while also pursuing use patents for post-infection respiratory complications and conducting research into neurological disorders. As treatments in the same drug class are being applied to a wider range of conditions overseas, domestic companies' strategies to expand their indications are drawing attention.


When reviewing development progress, it is important to distinguish between securing a use patent, confirming efficacy in clinical trials, and obtaining approval as a treatment. Even candidates in the same drug class may differ in their mechanisms of action and target diseases, so research findings from each company need to be examined individually. If follow-up research demonstrates differentiated efficacy, it could help South Korea's pharmaceutical industry expand its business base beyond obesity treatment into chronic diseases.


Meanwhile, All New Stock Loan is drawing interest by offering products with a range of terms, including options with annual interest rates in the 5% range. It is considered one option for investors seeking to broaden their investment opportunities while also taking cost burdens into account.

Beyond Weight Loss to Liver and Lung Diseases... Obesity Drug Development Expands View original image

◆ All New Stock Loan launches a product with an industry-low annual interest rate in the 5% range!

All New Stock Loan has launched a securities-linked credit product with an industry-low annual interest rate in the 5% range, so that any investor can use a stock loan without undue burden. The product can be used to purchase stocks and refinance brokerage margin balances or credit loans. Regardless of credit rating, users can access up to four times their own capital, including that capital. Investors using the alternative trading system (NXT) can also use the product.


Investors who would like to learn more about All New Stock Loan can contact the customer service center at 1599-8666 to speak with a professional adviser at any time, whether or not they qualify for a loan.


○ Industry-low annual interest rate in the 5% range!

○ ETF trading available

○ Access stock-buying funds of up to four times your own capital!

○ Same-day refinancing of brokerage credit loans or margin balances!

○ Trading available on the alternative trading system (NXT)

○ OK to buy stocks that were difficult to purchase using existing brokerage credit or stock loans!

* All New Stock Loan Customer Service Center: 1599-8666

Link: https://allnewstockloan.co.kr


SK hynix, SK Square, Daeduck Electronics, Hanmi Pharmaceutical, Hanmi Semiconductor



※ This content does not reflect the editorial direction of The Asia Business Daily. The information provider is solely responsible for all content.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing